{"nctId":"NCT03086343","briefTitle":"A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs","startDateStruct":{"date":"2017-05-09","type":"ACTUAL"},"conditions":["Rheumatoid Arthritis (RA)"],"count":657,"armGroups":[{"label":"Primary Cohort: Abatacept/Upadacitinib 15 mg QD","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Abatacept","Drug: Upadacitinib","Drug: Placebo for upadacitinib"]},{"label":"Primary Cohort: Upadacitinib 15 mg QD/Upadacitinib 15 mg QD","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)","Drug: Upadacitinib"]},{"label":"30 mg Cohort: Upadacitinib 30 mg QD/Upadacitinib 30 mg QD","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)","Drug: Upadacitinib"]},{"label":"30 mg Cohort: Abatacept/Upadacitinib 30 mg QD","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Abatacept","Drug: Upadacitinib","Drug: Placebo for upadacitinib"]}],"interventions":[{"name":"Abatacept","otherNames":[]},{"name":"Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)","otherNames":[]},{"name":"Upadacitinib","otherNames":["ABT-494"]},{"name":"Placebo for upadacitinib","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Main Inclusion Criteria:\n\n* Diagnosis of rheumatoid arthritis (RA) for ≥ 3 months who also fulfill the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for RA\n* Participants have been treated for ≥ 3 months prior to the screening visit with ≥ 1 bDMARD therapy, but continue to exhibit active RA or had to discontinue due to intolerability or toxicity, irrespective of treatment duration and have never received abatacept prior to the first dose of study drug\n* Participants have been receiving csDMARD therapy ≥ 3 months and on a stable dose for ≥ 4 weeks prior to the first dose of study drug. The following csDMARDs are allowed: methotrexate (MTX), sulfasalazine, hydroxychloroquine, chloroquine, and leflunomide. A combination of up to two background csDMARDs is allowed except the combination of MTX and leflunomide\n* Meets the following criteria: ≥ 6 swollen joints (based on 66 joint counts) and ≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits and high-sensitivity C-reactive protein (hsCRP) ≥ 3 mg/L at Screening\n\nMain Exclusion Criteria:\n\n* Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to upadacitinib, tofacitinib, baricitinib and filgotinib)\n* Prior exposure to abatacept\n* History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than RA. Current diagnosis of secondary Sjogren's Syndrome is permitted\n* Laboratory values meeting the following criteria within the Screening period prior to the first dose of study drug: serum aspartate transaminase \\> 2 × upper limit of normal (ULN); serum alanine transaminase \\> 2 × ULN; estimated glomerular filtration rate by simplified 4-variable Modification of Diet in Renal Disease formula \\< 40 mL/minute/1.73 meter (m)\\^2; total white blood cell count \\< 2,500/ μL; absolute neutrophil count \\< 1,500/μL; platelet count \\< 100,000/μL; absolute lymphocyte count \\< 800/μL; and hemoglobin \\< 10 g/dL","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Non-inferiority)","description":"The Disease Activity Score (DAS) 28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline indicates improvement in disease activity.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.52","spread":null},{"groupId":"OG001","value":"-2.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Superiority)","description":"The Disease Activity Score (DAS) 28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline indicates improvement in disease activity.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.52","spread":null},{"groupId":"OG001","value":"-2.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Clinical Remission (CR) Based on Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Superiority)","description":"The Disease Activity Score (DAS) 28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS 28 score less than 2.6 indicates clinical remission.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.0","spread":null},{"groupId":"OG001","value":"13.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":332},"commonTop":["URINARY TRACT INFECTION","COVID-19","UPPER RESPIRATORY TRACT INFECTION","NASOPHARYNGITIS","RHEUMATOID ARTHRITIS"]}}}